6533b7d5fe1ef96bd1264f7d

RESEARCH PRODUCT

Intravesical Treatment of Superficial Urinary Bladder Tumours with Adriamycin

D MelloniM Pavone-macaluso

subject

medicine.medical_specialtyUrinary bladderbusiness.industryCarcinoma in situUrologymedicine.diseaseResectionNeck of urinary bladderTransitional cell carcinomaIntravesical treatmentmedicine.anatomical_structureIntravesical instillationmedicinebusinessProphylactic treatment

description

Personal experience resulted in the observation that intravesical Adriamycin (ADM) is effective in some patients with multiple or diffuse papillary bladder tumours. A review of the literature shows that similar results have been obtained elsewhere, especially in Japan and Sweden. The response rate was higher if single doses of at least 50 mg were employed. Intravesical instillations of ADM appear to be valuable also in the treatment of carcinoma in situ and in prophylactic treatment after transurethral resection (TUR) of papillary bladder tumours.

yearjournalcountryeditionlanguage
1980-01-01
https://doi.org/10.1007/978-1-4613-3030-1_62